9:31 AM
 | 
Nov 02, 2017
 |  BC Extra  |  Financial News

Spero sags after $77M listing

Spero Therapeutics Inc. (NASDAQ:SPRO) sank $2.50 (18%) to $11.50 on Thursday after raising $77 million through the sale of 5.5 million shares at $14 in an IPO underwritten by BofA Merrill Lynch, Cowen, Stifel and Oppenheimer. The price, which was at the bottom end of Spero's proposed range, valued...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >